These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 14518596

  • 1. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G.
    Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
    [Abstract] [Full Text] [Related]

  • 2. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
    Celi M, Letizia C, Ragno A, Minisola S, D'Erasmo E, Mazzuoli GF.
    Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970
    [Abstract] [Full Text] [Related]

  • 3. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M, Balducci S, Schiappoli A, Caliumi C, Petramala L, Cerci S, Cotesta D, D'Erasmo E, Letizia C.
    Ann Ital Med Int; 2003 Dec; 18(2):89-98. PubMed ID: 12886826
    [Abstract] [Full Text] [Related]

  • 4. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 5. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M, Quarta L, Calcagnile F, Quarta E.
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [Abstract] [Full Text] [Related]

  • 6. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 7. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 17; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 8. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR, Wu YY, Zhang ZL, Yang X, Hui Y, Zhang Y, Chen SL, Den WH, Liu H, Ekangaki A, Stocks J, Harper K, Liu JL.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr 17; 38(4):226-9. PubMed ID: 12885371
    [Abstract] [Full Text] [Related]

  • 9. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.
    Menopause; 2006 Apr 17; 13(3):377-86. PubMed ID: 16735934
    [Abstract] [Full Text] [Related]

  • 10. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun 17; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

  • 11. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug 17; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 12. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr 17; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 13. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 17; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 17; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.